Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
30 March 2015 |
Main ID: |
EUCTR2013-001835-33-IT |
Date of registration:
|
09/08/2013 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Comparison of two ways of LCZ696 titration in heart failure patients
|
Scientific title:
|
A multicenter, randomized, double-blind, parallel group study to assess the safety and tolerability of initiating LCZ696 in heart failure patients comparing two titration regimens. |
Date of first enrolment:
|
25/11/2013 |
Target sample size:
|
480 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-001835-33 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: yes
Other specify the comparator: Comparison of two up-titration regimens with LCZ696
Number of treatment arms in the trial: 2
|
Phase:
|
|
|
Countries of recruitment
|
Bulgaria
|
Canada
|
Czech Republic
|
Finland
|
Germany
|
Hungary
|
Italy
|
Norway
|
Slovakia
|
Spain
|
Turkey
|
United Kingdom
|
United States
| | | |
Contacts
|
Name:
|
Drug Regulatory Affairs
|
Address:
|
Largo Umberto Boccioni, 1
21040
Origgio (VA)
Italy |
Telephone:
|
+390296541 |
Email:
|
info.studiclinici@novartis.com |
Affiliation:
|
Novartis Farma SpA |
|
Name:
|
Drug Regulatory Affairs
|
Address:
|
Largo Umberto Boccioni, 1
21040
Origgio (VA)
Italy |
Telephone:
|
+390296541 |
Email:
|
info.studiclinici@novartis.com |
Affiliation:
|
Novartis Farma SpA |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: Age = 18 years.
Chronic Heart Failure with New York Heart Association class II-IV.
Left ventricularejection fraction = 35%.
Patients must be treated with beta-blockers.
Other protocol-defined inclusion criteria may apply. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 240 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 240
Exclusion criteria: Potassium > 5.2 mmol/l.
Estimated glomerular filtration rate < 30 ml/min/1.73 m2.
Systolic blood pressure <100 mmHg or > 180 mmHg.
History of intolerance to recommended target doses of angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
Other protocol-defined exclusion criteria may apply.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
|
Chronic heart failure MedDRA version: 16.0
Level: LLT
Classification code 10008908
Term: Chronic heart failure
System Organ Class: 100000004849
|
Intervention(s)
|
Product Name: LCZ696 50mg Product Code: LCZ696 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: not available Other descriptive name: LCZ696 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use
Product Name: LCZ696 100mg Product Code: LCZ696 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: not available Other descriptive name: LCZ696 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use
Product Name: LCZ696 200mg Product Code: LCZ696 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: not available Other descriptive name: LCZ696 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use
|
Primary Outcome(s)
|
Secondary Objective: To evaluate the proportion of patients in the two treatment groups who achieve treatment success. To evaluate the proportion of patients who tolerate a regimen of LCZ696 200 mg bid for at least 2 weeks leading to study completion.
|
Timepoint(s) of evaluation of this end point: 12 weeks
|
Primary end point(s): Percentage of patients experiencing specified adverse events. Percentage of patients with systolic blood pressure < 95 mmHg. Percentage of patients with abnormal serum creatinine and doubling of serum creatinine. Percentage of patients with Serum potassium > 5.5 mmol/l and = 6.0 mmol/l.
|
Main Objective: To assess the safety and tolerability of initiating LCZ696 in heart failure patients with reduced ejection fraction using conservative (reaching target dose over 6 weeks) and condensed (reaching target dose over 3 weeks) up-titration regimens.
|
Secondary Outcome(s)
|
Secondary end point(s): Percentage of patients who achieve treatment success.
Percentage of patients who tolerate study medication for at least the last two weeks of the study.
|
Timepoint(s) of evaluation of this end point: 12 weeks
|
Secondary ID(s)
|
2013-001835-33-HU
|
CLCZ696B2228
|
Source(s) of Monetary Support
|
Novartis Pharma Services AG
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|